Innovative, Patient-Centric Therapies
Haim Pharma is committed to advancing patient-focused treatments through collaboration with leading research teams and strict adherence to pharmaceutical standards. We are pioneering new approaches that go beyond symptom management to deliver truly transformative, disease-modifying solutions for neurodegenerative conditions.
Key Product Features
Enhanced Stability
Engineered for optimized stability, our formulations are designed to ensure consistent efficacy and long shelf life, providing patients with reliable treatments they can trust.
Pharmaceutical Dosing Precision
Each dose is carefully controlled and precisely formulated to meet pharmaceutical standards, ensuring maximum therapeutic benefit while minimizing side effects.
Regulatory Compliance and Quality Control
Our development process aligns with regulatory standards, incorporating extensive quality control at each stage to ensure patient safety and product integrity.
Therapeutic Advantages
Supports Neuroplasticity
Our formulations are designed to promote neuroplasticity, enhancing the brain’s capacity for adaptation and recovery by fostering the growth and strengthening of neural connections.
Reduces Neuroinflammation
Chronic inflammation is a common challenge in neurodegenerative diseases. Our approach aims to minimize inflammation, potentially slowing disease progression and improving patient outcomes.
Minimizes Unwanted Psychoactive Effects
Unlike many traditional psychedelic approaches, Haim Pharma’s formulations are carefully balanced to reduce or avoid unwanted psychoactive effects, prioritizing clarity and daily functionality for patients.
A Multimodal Therapeutic Strategy
Psilocin’s ability to target multiple key pathways, such as neuroprotection, serotonin modulation, and inflammation, makes it an ideal candidate for addressing the complex mechanisms involved in neurodegenerative diseases. By working across these critical pathways, psilocin holds promise for slowing disease progression and enhancing brain resilience, offering a comprehensive approach to tackling neurodegeneration.
Focused on Neurodegenerative Diseases
Haim Pharma is focused on being a leader in safe, effective therapies for neurodegenerative diseases. Our research and development efforts are currently dedicated to conditions with urgent treatment needs, including:
Amyotrophic Lateral Sclerosis (ALS) / Frontotemporal Dementia (FTD)
Developing therapies to support motor function, cognitive resilience, and quality of life in ALS and FTD patients.
Parkinson’s Disease (PD)
Advancing treatments to improve motor control, cognitive function, and emotional well-being in Parkinson’s patients.
Alzheimer’s Disease (ALZ)
Targeting pathways that may enhance memory, cognitive function, and neuroprotection for those affected by Alzheimer’s.
Our approach positions Haim Pharma as a pioneer in delivering groundbreaking, patient-centered therapies that address the root causes of neurodegenerative diseases.
